2026 BioPharma eMarketing Summit

Every pharma company has run an AI pilot. Most of them are gathering dust. This session isolates the pivotal decisions that separate companies still experimenting from those running AI at enterprise scale — covering model governance, content supply, data readiness, change management, and why your biggest blocker isn't technology.

Moving Beyond AI Experimentation to Decision-Grade Intelligence

Pharma marketing has entered the Intelligence Economy, where success depends on turning authentic data into trusted, actionable intelligence. As marketers become intelligence workers, organizations must move beyond AI experimentation toward AI operationalism using human-led, AI-powered systems to improve not just efficiency, but decision quality, strategic effectiveness, and competitive advantage. This session explores why generic AI falls short in regulated healthcare environments and how purpose-built intelligence systems combining human expertise with healthcare-optimized AI can deliver more compliant, relevant, and decision-grade insights from patient, APP, and HCP conversations.

Key Takeaways

• The Rise of the Intelligence Economy: Why Pharma marketers must evolve into intelligence-driven organizations.
• From AI Experimentation to AI Operationalism: How to operationalize AI for real business impact, not just pilots and hype.
• Why Generic AI Fails in Pharma: The risks of hallucinations, shallow insights, and non-compliant AI outputs.
• Human-Led, AI-Powered Advantage: How human expertise + healthcare AI creates smarter, safer decisions.
• Beyond Efficiency to Effectiveness: Using AI to improve strategy, relevance, agility, and competitive advantage.

Pharma marketers are sitting on a goldmine of data, but it often lives in silos. This session explores how uniting digital engagement signals with syndicated datasets can unlock a true 360° view of HCP behavior. Learn how leading teams are overcoming integration challenges, ensuring compliance, and transforming raw data into actionable insights that drive precision targeting and smarter engagement strategies.

The biopharma industry has spent the last two years optimizing for AI — and somewhere in the process, lost sight of the human on the other end of the screen. Algorithms surface content. Platforms distribute it. But it's still a shopper who decides to trust it, click it, buy it, and come back for it. In this session, Mindy Sabel of Bayer cuts through the AI noise with something the industry is hungry for: a clear, practical playbook built on real shopper behavior and real revenue results. Drawing from the front lines of one of the world's leading consumer health brands, Mindy shows exactly how to show up — and stay visible — across search, social, and AI-powered discovery without sacrificing the authenticity that actually converts. She makes the case that the brands winning in an AI-first world aren't the ones who mastered the algorithm. They're the ones who never stopped listening to the shopper. Attendees will leave with a concrete framework for turning authentic customer voices into durable trust and reach, and for building connected experiences that carry shoppers all the way from first discovery to repeat choice.

Biopharma has spent decades designing two separate journeys — one for the HCP, one for the patient — and wondering why neither one feels complete. In this session, Karen Root argues that the HCP–patient silo isn't a workflow problem or a technology gap. It's a worldview problem, and it's costing the industry trust, adherence, and outcomes. Drawing on cross-industry CX frameworks and real examples from inside pharma, Karen makes the case for treating customer experience as systems-level infrastructure — not a campaign, not a channel, and not a committee. Attendees will leave with a clear model for closing the loop: unified signals, orchestrated touchpoints, and a single accountable function that owns the full journey from first awareness to long-term adherence.

Every other industry has figured out how to make influencer marketing work. Pharma figured out how to make it disappear. Somewhere between the fair balance requirement, the MLR review cycle, and the fear of an FDA warning letter, the industry built an influencer program that checks every compliance box — and moves no one. In this session, a pharma brand marketer makes an uncomfortable argument: regulatory caution isn't what's killing pharma influencer strategy. Cowardice dressed up as caution is. Drawing from campaigns that navigated the regulatory landscape without surrendering creative impact, this talk reframes the compliance framework not as a ceiling, but as a brief — the most honest creative brief the industry has ever been handed. Attendees will leave with a new mental model for briefing, selecting, and activating influencers inside a regulated environment, and a clear-eyed view of where the real risk actually lives: not in the post, but in saying nothing at all.

Pharma excels at winning the moment. The detail lands. The campaign performs. The prescription is written. Then the journey falls apart, and so does the revenue. When commercial organizations are built around siloed roles optimized for influence, nobody owns what happens next. Reimbursement stalls. Fulfillment fragments. Patients never start. Value leaks quietly out of a system designed to generate intent, not protect it. Field organizations bear the weight of that broken architecture every day, navigating complexity that was never theirs to solve alone. This session is about making the shift to Consumer-Grade thinking, from managing moments to governing journeys.